666 related articles for article (PubMed ID: 32072644)
1. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
2. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.
Cornez I; Yajnanarayana SP; Wolf AM; Wolf D
Mol Cell Endocrinol; 2017 Aug; 451():88-96. PubMed ID: 28131742
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
7. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
8. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
Karati D; Mahadik KR; Trivedi P; Kumar D
Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
[TBL] [Abstract][Full Text] [Related]
12. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
13. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
14. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
19. Small molecule drug discovery targeting the JAK-STAT pathway.
Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
[TBL] [Abstract][Full Text] [Related]
20. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
